NRx Pharmaceuticals announced the formation of NRx Defense Systems Inc., a Florida-based research and development subsidiary dedicated to advancing neuroplastic treatments combining D-cycloserine and transcranial magnetic stimulation supported by robotic-enabled neuronavigation. The subsidiary will be led by Dr. Dennis McBride, with support from Chief Medical Innovation Officer Dr. Joshua Brown.
Goals and Partnerships
NRx Defense Systems aims to pursue non-dilutive government and institutional funding while developing deployable solutions for military and first responder use. The subsidiary is developing a prototype in partnership with Zeta Surgical Inc., expected to be unveiled at the Clinical TMS Society annual meeting in June 2026.
NRx Pharmaceuticals is a biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for suicidal ideation in depression, including bipolar depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression.
NRx has filed an Abbreviated New Drug Application and initiated a New Drug Application filing for NRX-100 with an application for the Commissioner’s National Priority Voucher Program for treating suicidal ideation in patients with depression, including bipolar depression.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.financialcontent.com/article/nnwire-2026-4-15-biomednewsbreaks-nrx-pharmaceuticals-inc-nasdaq-nrxp-forms-nrx-defense-systems-subsidiary-to-advance-neuroplastic-therapies-for-military-and-government-applications